Viromed Medical AG (ISIN: DE000A40ZVN7), a pioneer in cold plasma technology, announced the successful completion of a multi-year study investigating the application of cold atmospheric plasma (CAP) in the lung. The study focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine. Results confirm a clearly defined therapeutic safety window and complete reduction of pathogenic germs in lung epithelial models, according to the company's press release.
The research included ex vivo validation on vital lungs in collaboration with Saarland University and Hannover Medical School. The isolated, ventilation- and perfusion-capable lung model used realistically reflects key physiological characteristics of the human lung, enabling reproducible investigations on vital organ tissue. Study data will now be submitted for publication in a renowned scientific journal.
Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated: "By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems of the human body." He added that the technology has already shown impressive potential in patient applications, opening a new chapter in intensive care and infectious medicine.
Based on these results, the technology has been used in a university setting for a severe pulmonary individual case in a human patient. Following ethics committee approval, a university hospital with a department specializing in lung and transplantation medicine treated a patient with massive complications after a lung transplant. The use of cold plasma was very successful, and according to the treating physicians, the observed positive clinical course was exceptional. The hospital plans to publish the case soon, and further severely ill patients with a high risk of fatal outcome are undergoing treatment.
Viromed sees clear indications that cold plasma technology will fundamentally change pneumology. While classical pharmacological therapies are increasingly limited by resistance development, cold plasma as a physical mode of action opens a new therapeutic dimension, including prevention of severe pulmonary infections. Looking ahead, further applications in intensive care medicine are moving into clinical research, such as intracardiac use in operations for bacterial endocarditis or application in the thorax for bacterial pleural empyema.
The company's operating business focuses on distributing innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed draws on a broad customer base in the DACH region and beyond. More information is available at www.viromed-medical-ag.de.
